Lorenzo Antonuzzo

15PUBLICATIONS
139CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nonlinear optics and spectroscopyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 26, 2026
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy.

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Aug 18, 2026
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

|Jul 07, 2025
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Lorenzo Antonuzzo, Hidenori Takahashi, Joon Oh Park

|Jul 17, 2024
Delineation of gastrointestinal tumors biopsies using a fluorescence lifetime imaging optical fiber probe.

D Suraci, E Baria, L Tirloni

|Feb 21, 2024
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo

Pageof 3

Frequent Collaborators

3 joint publications

Serena Pillozzi

2 joint publications

Alessandro Parisi

2 joint publications

Giandomenico Roviello

2 joint publications

Vincenzo Formica